CAR and TCR form individual signaling synapses and do not cross-activate, however, can co-operate in T cell activation.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 28 11 2022
accepted: 17 01 2023
entrez: 23 2 2023
pubmed: 24 2 2023
medline: 3 3 2023
Statut: epublish

Résumé

In engineered T cells the CAR is co-expressed along with the physiological TCR/CD3 complex, both utilizing the same downstream signaling machinery for T cell activation. It is unresolved whether CAR-mediated T cell activation depends on the presence of the TCR and whether CAR and TCR mutually cross-activate upon engaging their respective antigen. Here we demonstrate that the CD3ζ CAR level was independent of the TCR associated CD3ζ and could not replace CD3ζ to rescue the TCR complex in CD3ζ KO T cells. Upon activation, the CAR did not induce phosphorylation of TCR associated CD3ζ and, vice versa, TCR activation did not induce CAR CD3ζ phosphorylation. Consequently, CAR and TCR did not cross-signal to trigger T cell effector functions. On the membrane level, TCR and CAR formed separate synapses upon antigen engagement as revealed by total internal reflection fluorescence (TIRF) and fast AiryScan microscopy. Upon engaging their respective antigen, however, CAR and TCR could co-operate in triggering effector functions through combinatorial signaling allowing logic "AND" gating in target recognition. Data also imply that tonic TCR signaling can support CAR-mediated T cell activation emphasizing the potential relevance of the endogenous TCR for maintaining T cell capacities in the long-term.

Identifiants

pubmed: 36817444
doi: 10.3389/fimmu.2023.1110482
pmc: PMC9929185
doi:

Substances chimiques

CD3 Complex 0
Receptor-CD3 Complex, Antigen, T-Cell 0
Receptors, Antigen, T-Cell 0
Receptors, Chimeric Antigen 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1110482

Informations de copyright

Copyright © 2023 Barden, Holzinger, Velas, Mezősi-Csaplár, Szöőr, Vereb, Schütz, Hombach and Abken.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Nat Med. 2015 Jun;21(6):581-90
pubmed: 25939063
Bioinformatics. 2013 Jul 15;29(14):1840-1
pubmed: 23681123
Blood. 2020 Sep 17;136(12):1407-1418
pubmed: 32483603
Sci Transl Med. 2017 Jan 25;9(374):
pubmed: 28123068
Nature. 2020 Sep;585(7825):357-362
pubmed: 32939066
Blood. 1996 May 1;87(9):3593-9
pubmed: 8611682
J Allergy Clin Immunol. 2017 Jan;139(1):347-349.e8
pubmed: 27555457
J Gen Virol. 1977 Jul;36(1):59-74
pubmed: 886304
Front Immunol. 2021 Mar 23;12:639818
pubmed: 33833759
Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2474-9
pubmed: 21282657
Clin Exp Immunol. 2000 Apr;120(1):174-82
pubmed: 10759780
J Immunol. 2001 Aug 1;167(3):1290-6
pubmed: 11466345
J Immunol. 2004 Dec 15;173(12):7647-53
pubmed: 15585893
J Immunol. 1998 Jul 1;161(1):375-84
pubmed: 9647246
Immunity. 2020 Aug 18;53(2):456-470.e6
pubmed: 32758419
J Clin Invest. 1997 Mar 1;99(5):915-25
pubmed: 9062349
Gene Ther. 1998 Sep;5(9):1195-203
pubmed: 9930320
Int J Mol Med. 1998 Jul;2(1):99-103
pubmed: 9854151
Blood. 2017 Sep 7;130(10):1205-1208
pubmed: 28743717
Int J Mol Sci. 2020 Oct 08;21(19):
pubmed: 33050044
Sci Signal. 2019 Feb 12;12(568):
pubmed: 30755478
Nat Methods. 2020 Mar;17(3):261-272
pubmed: 32015543
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
J Immunol Methods. 1992 Mar 4;147(2):153-65
pubmed: 1548398
Mol Ther. 2017 Apr 5;25(4):949-961
pubmed: 28237835
Gene Ther. 1999 Feb;6(2):300-4
pubmed: 10435115
Sci Signal. 2018 Aug 21;11(544):
pubmed: 30131370
J Cell Biol. 2023 Feb 6;222(3):
pubmed: 36520493
Nat Biotechnol. 2013 Jan;31(1):71-5
pubmed: 23242161
Clin Cancer Res. 2019 Dec 15;25(24):7340-7350
pubmed: 31558475
Sci Transl Med. 2015 Sep 2;7(303):303ra139
pubmed: 26333935
PLoS One. 2012;7(1):e30713
pubmed: 22292024
Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720-4
pubmed: 8421711
Blood. 2007 Oct 1;110(7):2620-30
pubmed: 17507664
Mol Ther. 2018 Sep 5;26(9):2218-2230
pubmed: 30055872
J Immunol. 2001 Dec 1;167(11):6123-31
pubmed: 11714771
J Immunol. 1998 Jul 15;161(2):1000-6
pubmed: 9670981
Gene Ther. 2003 Aug;10(17):1408-19
pubmed: 12900755
Immunity. 1995 Jun;2(6):639-44
pubmed: 7796297
Oncotarget. 2018 Apr 3;9(25):17608-17619
pubmed: 29707134
Hum Gene Ther Methods. 2017 Dec;28(6):302-309
pubmed: 28741380
Sci Signal. 2021 Aug 24;14(697):
pubmed: 34429382

Auteurs

Markus Barden (M)

Leibniz Institute for Immunotherapy (LIT), Division of Genetic Immunotherapy, University Regensburg, Regensburg, Germany.

Astrid Holzinger (A)

Leibniz Institute for Immunotherapy (LIT), Division of Genetic Immunotherapy, University Regensburg, Regensburg, Germany.

Lukas Velas (L)

Institute of Applied Physics, TU Wien, Vienna, Austria.

Marianna Mezősi-Csaplár (M)

Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Árpád Szöőr (Á)

Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

György Vereb (G)

Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
ELKH-DE Cell Biology and Signaling Research Group, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Gerhard J Schütz (GJ)

Institute of Applied Physics, TU Wien, Vienna, Austria.

Andreas A Hombach (AA)

Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
Department I Internal Medicine, University Hospital Cologne, Cologne, Germany.

Hinrich Abken (H)

Leibniz Institute for Immunotherapy (LIT), Division of Genetic Immunotherapy, University Regensburg, Regensburg, Germany.

Articles similaires

Humans Receptors, Antigen, T-Cell Proto-Oncogene Proteins p21(ras) Pancreatic Neoplasms T-Lymphocytes

The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma.

Arianna Giacomini, Sara Taranto, Giorgia Gazzaroli et al.
1.00
Humans Multiple Myeloma Receptors, Fibroblast Growth Factor Fibroblast Growth Factors Proto-Oncogene Proteins c-myc
Animals Lung India Sheep Transcriptome

Calcineurin inhibition enhances

Priyanka Das, Alejandro Aballay, Jogender Singh
1.00
Animals Caenorhabditis elegans Longevity Caenorhabditis elegans Proteins Calcineurin

Classifications MeSH